Rhythm Says European Medicines Agency's CHMP Adopted Positive Opinion Recommending Marketing Authorization For IMCIVREE; European Commission Decision Anticipated In H2 Of 2024
Portfolio Pulse from Benzinga Newsdesk
Rhythm Pharmaceuticals announced that the European Medicines Agency's CHMP has adopted a positive opinion recommending marketing authorization for IMCIVREE to include children aged 2 to under 6 with obesity due to specific genetic conditions. A decision from the European Commission is expected in the second half of 2024.
June 28, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Rhythm Pharmaceuticals received a positive opinion from the EMA's CHMP for expanding the use of IMCIVREE to young children with specific genetic obesity conditions. This regulatory milestone could lead to increased market potential in Europe, pending a decision from the European Commission in H2 2024.
The positive opinion from the EMA's CHMP is a significant regulatory milestone for Rhythm Pharmaceuticals. If the European Commission follows through with a marketing authorization in H2 2024, it could expand the market for IMCIVREE, potentially boosting revenues and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100